Evidence map›Paper›PMID 41243501›Full record

ArticlePathologica2025

HER2-positive neuroendocrine breast carcinoma: a case study uncovers

Margherita Zordan, Elena Fiorio, Valeria Maffeis, Andrea Mafficini, Giulia Querzoli, Bianca Barioglio, Pamela Biondani, Matteo Brunelli, Alessandra Invento, Francesca Pellini and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Margherita ZordanDepartment of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy.
Elena FiorioDepartment of Medicine, Section of Oncology, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Valeria MaffeisDepartment of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy.
Andrea MafficiniDepartment of Engineering for Innovation Medicine (DIMI), University of Verona, Verona, Italy.
Giulia QuerzoliDepartment of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy.
Bianca BarioglioDepartment of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy.
Pamela BiondaniDepartment of Medicine, Section of Oncology, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Matteo BrunelliDepartment of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy.
Alessandra InventoComplex Operative Unit Breast Surgery, Breast Unit, Oncology Department, University and Hospital Trust of Verona, Verona, Italy.
Francesca PelliniComplex Operative Unit Breast Surgery, Breast Unit, Oncology Department, University and Hospital Trust of Verona, Verona, Italy.
Claudio LuchiniDepartment of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy.
Aldo ScarpaDepartment of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy.
Alessia NottegarDepartment of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary neuroendocrine carcinoma of the breast (NEBC) is a rare entity among breast malignancies, and is usually associated with a more aggressive clinical course compared to other types of invasive breast cancer. Although some studies have characterized the molecular profile of NEBCs using targeted sequencing, these tumors are often treated similarly to other primary breast carcinomas despite their unique morpho-phenotypic characteristics. In this study, we present the case of a woman with HER2-positive primary large cell NEBC with homolateral axillary nodal metastases. After neoadjuvant therapy, the patient underwent surgical resection of the breast, showing a partial pathological response. Next-generation sequencing was performed on pre- and post-treatment samples using a 174-genes panel. Both samples exhibited a similar molecular profile, including a somatic mutation in This study represents the first report of

Indexed as

Breast NeoplasmsCarcinoma, NeuroendocrineCyclin D1Erb-b2 Receptor Tyrosine KinasesFibroblast Growth FactorsReceptor, IGF Type 1Receptors, SomatomedinAdultBiomarkers, TumorFemaleGene AmplificationHumansBiomarkers, TumorCCND1 protein, humanCyclin D1ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFGF19 protein, humanFibroblast Growth FactorsIGF1R protein, humanReceptor, IGF Type 1Receptors, SomatomedinFGF19gene amplification (CCND1HER2IGF1R)molecular profilingneuroendocrine breast carcinomaprecision oncology

Identifiers

PMID41243501
PMCPMC12620945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.